Immunomic Therapeutics to present at Swiss Skin Vaccination Summit
The presentation, which is about the company’s unique LAMP-vax platform, is titled "Immunization with ARA H-LAMP-vax peanut vaccine protects and blocks IgE-mediated anaphylaxis in a peanut allergic murine model."
The presentation will be given by Terri Heiland, Ph.D., the company’s vice president of research and development. The presentation is scheduled for 10:20 a.m. local time on Sept. 3, 2015.
Dr. Heiland co-authored the posted, titled "Manufacture and Needle-Free, Intradermal Delivery of Antibiotic Free NTC RNA-Out LAMP-vax Plasmids.” This study was conducted to demonstrate that using a Biojector device with the LAMP-vax formulation provokes antibodies better than traditional injection methods.
"These presentations and posters represent significant advancement in the development LAMP-vax, particularly with regard to peanut allergies," William Hearl, Ph.D., CEO of ITI, said. "As we continue to gather data regarding our technology and its application to treating peanut allergies, we are encouraged by what we are learning regarding the potential of our development programs. This work could allow for significant improvement in the lives of those who have suffered with allergies, particularly food allergies, with no viable solutions to date."